Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis

You may be eligible if

• PROTOCOL ENTRY CRITERIA:
• -Disease Characteristics--
• Clinically or laboratory-supported definite multiple sclerosis
• Neurologically stable for at least 30 days prior to entry Expanded Disability Status Scale score no greater than 5
• At least 2 documented relapses within 2 years prior to entry Onset of first relapse at least 1 year prior to randomization
• -Prior/Concurrent Therapy--
• Biologic therapy: No prior copolymer 1
• Immunosuppressive therapy: No prior cytotoxic immunosuppressives, i.e.: Azathioprine Cyclophosphamide Cyclosporine At least 30 days since corticosteroids
• Radiotherapy: No prior lymphoid irradiation
• -Patient Characteristics--
• Not HIV or HTLV-I seropositive No insulin-dependent diabetes mellitus No Lyme disease No requirement for aspirin or chronic nonsteroidal anti-inflammatory drugs No pregnant or nursing women Adequate contraception required of fertile women